in good shape Ramelteon Class: Anxiolytics, Sedatives, and Hypnotics; Miscellaneous VA Class: CN300 Chemical Name: N-[2-[8S)-1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl-propanamide Molecular Formula: C 16 H 21 NO 2 CAS Number: 196597-26-9 Brands: Rozerem Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Support Group Q & A Introduction Melatonin receptor agonist; hypnotic. 1 2 Uses for Ramelteon Insomnia Management of insomnia characterized by difficulty with sleep onset. 1 Decreases sleep latency in patients with transient insomnia. 1 2 Decreases sleep latency in patients with chronic insomnia receiving therapy for up to 35 days. 1 2 3 4 5 Slideshow Insomnia Treatment: Non-Benzodiazepines Ambien, Lunesta & Sonata Ramelteon Dosage and Administration Administration Oral Administration Administer orally within 30 minutes of bedtime. 1 2 Avoid administration with or immediately after a high-fat meal because of potentially decreased rate of absorption. 1 2 (See Food under Pharmacokinetics.) Dosage Adults Insomnia Oral 8 mg. 1 2 Special Populations Hepatic Impairment Increased exposure to drug and active metabolite. 1 (See Special Populations under Pharmacokinetics.) No specific dosage recommendations at this time. 1 However, use with caution in patients with moderate hepatic impairment; avoid use in patients with severe hepatic impairment. 1 Renal Impairment No dosage adjustment necessary in patients with mild, moderate, or severe renal impairment or in those requiring chronic hemodialysis. 1 Cautions for Ramelteon Contraindications Hypersensitivity to ramelteon or any ingredient in the formulation. 1 Warnings/Precautions Warnings Adequate Patient Evaluation Sleep disturbances may be a manifestation of a physical and/or psychiatric disorder; carefully evaluate patient before providing symptomatic treatment. 1 Failure of insomnia to remit after a reasonable treatment period, exacerbation of insomnia, and/or emergence of new cognitive or behavioral abnormalities may indicate the presence of an underlying psychiatric or physical disorder requiring further patient evaluation. 1 Complex Sleep-related Behaviors Potential risk of complex sleep-related behaviors such as sleep-driving (i.e., driving while not fully awake after ingesting a sedative-hypnotic drug, with no memory of the event), making phone calls, or preparing and eating food while asleep. 6 Sensitivity Reactions Potential risk of anaphylaxis and angioedema; may occur as early as with the first dose of drug. 6 Major Toxicities Psychiatric Effects Cognitive and behavioral changes reported. 1 In primarily depressed patients, exacerbation of depression and suicidal ideation reported following use of hypnotics. 1 Immediately evaluate any new psychiatric abnormalities. 1 Endocrine Effects Increased prolactin concentrations reported in patients with chronic insomnia receiving ramelteon 16 mg daily for 6 months. 1 Abnormal morning cortisol concentrations (resulting in abnormal corticotropin [ACTH] stimulation test results) reported in 2 patients and prolactinoma reported in 1 patient receiving long-term (up to 12 months) therapy; causal relationship to drug not established. 1 If unexplained amenorrhea, galactorrhea, decreased libido, or fertility problems occur, consider evaluating prolactin or testosterone concentrations. 1 Abuse Potential and Dependence No evidence of abuse potential detected following administration of doses up to 20 times the recommended hypnotic dose in patients with a history of drug abuse or dependence. 1 2 No evidence of physical dependence. 1 Withdrawal No evidence of a withdrawal syndrome, including rebound insomnia, following discontinuance of long-term therapy (4, 8, or 16 mg daily for up to 35 days). 1 2 Residual Effects Next-day residual effects (reduced immediate/delayed memory recall and increased sluggishness, fatigue, and irritation) detected at weeks 1 and 3 but not week 5 of therapy in adult patients receiving ramelteon 8 mg daily. 1 2 Residual effects not detected in a similar study in geriatric patients receiving ramelteon 4 or 8 mg daily. 1 2 General Precautions Long-term Safety No clinically meaningful changes in laboratory parameters, endocrine tests, vital signs, ECG recordings, or intensity of menstrual bleeding detected in patients with chronic insomnia following up to 1 year of therapy. 2 Rebound insomnia not observed following 1 year of therapy. 2 Concomitant Diseases No respiratory depressant effect in patients with mild to moderate COPD. 1 Effects in patients with severe COPD (e.g., those with elevated pCO 2 , those requiring nocturnal oxygen therapy) not studied; use in these patients not recommended. 1 No differences in measures of apnea indices observed in patients with mild to moderate obstructive sleep apnea. 1 Effects in patients with severe obstructive sleep apnea not studied; use in these patients not recommended. 1 Specific Populations Pregnancy Category C. 1 Lactation Distributed into milk in rats; not known whether distributed into human milk. 1 Use not recommended. 1 Pediatric Use Safety and efficacy not established in pediatric patients. 1 Geriatric Use Increased exposure to drug and active metabolite. 1 (See Special Populations under Pharmacokinetics.) However, no overall differences in safety or efficacy relative to younger adults. 1 Hepatic Impairment Use with caution in patients with moderate hepatic impairment; avoid use in patients with severe hepatic impairment. 1 (See Special Populations under Pharmacokinetics.) Common Adverse Effects Headache, somnolence, dizziness, fatigue, nausea, exacerbation of insomnia, upper respiratory tract infection, diarrhea, myalgia, depression, dysgeusia, arthralgia. 1 Interactions for Ramelteon Metabolized principally by CYP1A2 and, to a lesser extent, by the CYP2C subfamily and by CYP3A4. 1 Drugs Affecting Hepatic Microsomal Enzymes Inhibitors of CYP1A2: Potential pharmacokinetic interaction (substantially increased serum ramelteon concentrations). 1 Avoid concomitant use with strong CYP1A2 inhibitors; caution if used concomitantly with less potent CYP1A2 inhibitors. 1 Inhibitors of CYP3A4 and CYP2C9: Potential pharmacokinetic interaction (increased serum concentrations of ramelteon and active metabolite). 1 Caution if used concomitantly with potent inhibitors of CYP3A4 or CYP2C9. 1 Inducers of CYP isoenzymes: Potential pharmacokinetic interaction (decreased serum concentrations of ramelteon and active metabolite). 1 Possibly reduced ramelteon efficacy when used concomitantly with potent CYP inducers. 1 2 Drugs Metabolized by Hepatic Microsomal Enzymes Substrates of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, and 3A4: Pharmacokinetic interaction unlikely. 1 Specific Drugs Drug or Test Interaction Comments Alcohol Additive sedative effects 1 Avoid concomitant use 1 Dextromethorphan Pharmacokinetic interaction unlikely 1 Digoxin Pharmacokinetic interaction unlikely 1 Fluconazole Increased peak serum concentrations and AUC of ramelteon and active metabolite 1 Use concomitantly with caution 1 Fluoxetine Pharmacokinetic interaction unlikely 1 Fluvoxamine Substantially increased peak serum concentration and AUC of ramelteon 1 Avoid concomitant use 1 Ketoconazole Increased peak serum concentration and AUC of ramelteon and active metabolite 1 Use concomitantly with caution 1 Midazolam Pharmacokinetic interaction unlikely 1 Omeprazole Pharmacokinetic interaction unlikely 1 Rifampin Decreased peak serum concentration and AUC of ramelteon and active metabolite 1 Concomitant use may reduce efficacy of ramelteon 1 2 Theophylline Pharmacokinetic interaction unlikely 1 Warfarin Pharmacokinetic interaction unlikely 1 Urine Drug Screening No false-positive results for urine drug screening of benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines 1 Ramelteon Pharmacokinetics Absorption Bioavailability Rapidly absorbed; following oral administration in fasting state, peak serum concentrations occur at approximately 0.75 hour. 1 Total absorption is 84%; however, absolute oral bioavailability is 1.8% because of extensive first-pass metabolism. 1 Food High-fat meal delays time to peak serum concentration by 45 minutes, reduces peak serum concentration by 22%, and increases AUC by 31%. 1 (See Oral Administration under Dosage and Administration.) Special Populations In geriatric patients, peak serum concentrations and AUC of ramelteon are increased by 86 and 97%, respectively. 1 Peak serum concentrations and AUC of active metabolite also are increased, but to a lesser extent. 1 In patients with mild or moderate hepatic impairment, exposure to ramelteon is increased 4- or 10-fold, respectively. 1 Exposure to active metabolite is marginally increased. 1 Pharmacokinetic parameters not evaluated in patients with severe hepatic impairment (Child-Pugh class C). 1 (See Hepatic Impairment under Cautions.) Pharmacokinetic parameters not altered in patients with renal impairment or in those requiring chronic hemodialysis. 1 Distribution Extent Extensively distributed into tissues; not distributed selectively to red blood cells. 1 Plasma Protein Binding Approximately 82% (mainly [70%] albumin). 1 Elimination Metabolism Metabolized principally by CYP1A2 and, to a lesser extent, by the CYP2C subfamily and by CYP3A4 to active (M-II) and inactive metabolites. 1 Elimination Route Excreted in urine (84%) and feces (4%), principally as metabolites. 1 Half-life 1 2.6 hours (for ramelteon) and 2 5 hours (for active metabolite). 1 Stability Storage Oral Capsules Tightly-closed containers at 25 C (may be exposed to 15 30 C). 1 Protect from moisture and humidity. 1 Actions Exhibits high affinity for melatonin MT 1 and MT 2 receptors. 1 2 Agonist activity at these receptors may contribute to the drug s sleep-inducing properties. 1 2 Demonstrates lower selectivity for melatonin MT 3 receptors than for MT 1 and MT 2 receptors. 1 Has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates. 1 Advice to Patients Necessity of administering within 30 minutes of bedtime and limiting activities to only those necessary to prepare for bed. 1 Avoid administration with or immediately after a high-fat meal. 1 Necessity of avoiding driving, operating machinery, or performing hazardous tasks following administration. 1 Importance of avoiding alcohol during therapy. 1 Importance of consulting a clinician if worsening insomnia or emergence of new behavioral manifestations occurs. 1 Importance of consulting a clinician if cessation of menses or galactorrhea (in women), decreased libido, or problems with fertility occur. 1 Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. 1 Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses. 1 Importance of informing patients of other important precautionary information. 1 (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Ramelteon Routes Dosage Forms Strengths Brand Names Manufacturer Oral Tablets, film-coated 8 mg Rozerem Takeda AHFS DI Essentials. Copyright 2017, Selected Revisions October 21, 2014. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References 1. Takeda Pharmaceuticals America, Inc. Rozerem (ramelteon) tablets prescribing information. Lincolnshire, IL; 2005 Aug. 2. Takeda Pharmaceuticals America, Inc., Lincolnshire, IL: Personal communication. 3. Zammit G, Roth T, Erman M et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep . 2005; 28(Suppl):A228-9. 4. Roth T, Seiden D, Weigand S et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia. Proceedings of New Clinical Drug Evaluation Unit. June 6-9, 2005, Boca Raton, Fla. Poster abstract. 5. Roth T, Seiden D, Zee P et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients. J Am Geriatr Soc . 2005; 53(Suppl):S25. Abstract. 6. Food and Drug Administration. Rozerem (ramelteon) tablets. [March 14, 2007: Takeda] MedWatch drug labeling changes. Rockville, MD; April 2007. From FDA website. Next Interactions Print this page Add to My Med List More about ramelteon Side Effects During Pregnancy Dosage Information Drug Interactions Support Group En Español 66 Reviews Add your own review/rating Drug class: miscellaneous anxiolytics, sedatives and hypnotics Consumer resources Ramelteon Ramelteon (Advanced Reading) Professional resources Ramelteon (Wolters Kluwer) Other brands: Rozerem Related treatment guides Insomnia} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Miscellaneous anxiolytics, sedatives and hypnotics Related Drugs Insomnia melatonin , lorazepam , zolpidem , amitriptyline , Ambien , temazepam , Ativan , diphenhydramine , doxepin , Elavil , Restoril , Ibuprofen PM , Belsomra , Lunesta , eszopiclone , Rozerem , triazolam , zaleplon , doxylamine , Sonata , Silenor , Halcion , flurazepam , suvorexant , More... Ramelteon Rating 66 User Reviews 4.6 /10 66 User Reviews 4.6 Rate it!} } to accentuate
mother or father Ramelteon out of the blue
EmoticonEmoticon